December 2010
Plastic Surgery Practice;Dec2010, Vol. 20 Issue 12, p34
Product Review
The article evaluates skin care product Dermacyte® from Oxygen Biotherapeutics Inc.


Related Articles

  • Oxygen Biotherapeutics Announces 3rd Qtr FY2012 Financial Results Conference Call and Webcast.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article announces the medical and cosmetic products company Oxygen Biotherapeutics Inc. will host a conference call and webcast to discuss its third quartertr fiscal year 2012 financial results to be held on March 16, 2012.

  • Financings Roundup.  // BioWorld Today;6/18/2012, Vol. 23 Issue 117, p3 

    The article reports on agreements between Oxygen Biotherapeutics Inc. and institutional investors to amend the terms of an offering of registered shares of Series A convertible preferred stock and registered warrants.

  • Financings Roundup.  // BioWorld Today;4/1/2010, Vol. 21 Issue 62, p6 

    This article reports on the filing by Oxygen Biotherapeutics Inc. of a shelf registration to raise up to 75 million U.S. dollars through the sale of common stock.

  • Oxygen Biotherapeutics Announces FY2011 Year-End and Fourth Quarter Financial Results Conference Call and Webcast.  // Biomedical Market Newsletter;6/19/2011, p25 

    The article offers information on the conference call and webcast to be hosted by Oxygen Biotherapeutics Inc. on July 15, 2011 to discuss the financial results of the company for the fiscal year 2011.

  • Stock Movers.  // BioWorld Today;7/29/2013, Vol. 24 Issue 143, p2 

    A chart is presented that lists changes in the stocks of companies such as GW Pharmaceuticals plc, Idera Pharmaceuticals Inc., and Oxygen Biotherapeutics Inc. as of July 26, 2013.

  • Oxygen Biotherapeutics Buys Pharma Rights. COLLINS, ALLISON // Mergers & Acquisitions Report;10/28/2013, Vol. 28 Issue 43, p11 

    The article reports on the acquisition of pharmaceutical firm Phyxius Pharma's assets by Oxygen Biotherapeutics Inc. with the goal of developing a calcium sensitizer for prevention and treatment of patients who underwent cardiac surgery.

  • Oxygen moving new CV drug into pivotal trial; PFC work ongoing. Boggs, Jennifer // BioWorld Today;1/7/2014, Vol. 25 Issue 4, p1 

    The article reports on the progress of the acquired cardiovascular drug levosimendan by Morrisville, North Carolina-based Oxygen Biotherapeutics Inc., which increased shares of the firm up more than 20 percent. It notes the protocol for the planned phase III study of the calcium sensitizer which...

  • Anti Aging.  // Gifts & Decorative Accessories;Jul2011, Vol. 112 Issue 6, p134 

    The article offers information on the several anti-aging products including Nectar Agelesss Body Oil from Farmhouse Fresh, Dermacyte Oxygen concentrate from Oxygen Biotherapeutics Inc., and Baby's Butt anti-aging face primer from Addiction NV Cosmetics.

  • University of Glasgow Study Demonstrates the Ability of Oxycyte(r) to Supply Oxygen to Critical Penumbral Tissue in Acute Ischemic Stroke.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article presents information on a study conducted by Aurum Biosciences Ltd. which shows that Oxycyte, perfluorocarbon-based intravenous emulsion from Oxygen Biotherapeutics Inc. improves imaging of the penumbra following acute ischemic stroke. When a blood vessel that carries oxygen to a...

  • The Front on TBI Treatments. E. H. M.; E. M. // Officer;Nov2008, Vol. 84 Issue 9, p39 

    The article offers information on the hyperbaric oxygen therapy (HBOT), which pushes oxygen fuel into blood plasma and cerebralspinal fluid. It is said that HBOT is a sample of the research development in the treatment of traumatic brain injury (TBI). It is cited that Oxygen Biotherapeutics Inc....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics